Pfizer ( PFE 1.46%) made a fortune thanks to its work in the COVID-19 market. In 2022, it became the first company in the ...

Pfizer halted its oral obesity drug, danuglipron, in April 2025 due to liver injury concerns, a major pipeline setback. Find ...

Pfizer (PFE) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Pfizer remains a strong Buy with robust cost controls, EPS growth, and a promising pipeline, despite challenges. See more on ...

Pfizer’s stock surged up to 11 percent after the pharma giant reported a robust 85 percent year-on-year rise in net profit ...

Pfizer’s positive comments about the impact of a potential tariff being manageable led the stock to increase despite a softer quarterly performance. Nonetheless, a single quarter’s results are ...

Pfizer (PFE) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the ...

Pfizer (PFE) has seen its stock fall to its lowest level in 13 years as pressure from falling blockbuster drug sales weighs on performance. CEO Bourla maintains supporting the dividend is a high ...

Pfizer’s positive comments about the impact of a potential tariff being manageable led the stock to increase despite a softer quarterly performance. Nonetheless, a single quarter’s results are not so ...